<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="other">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Vaccine</journal-id>
      <journal-title>Vaccine</journal-title>
      <issn pub-type="ppub">0264-410X</issn>
      <publisher>
        <publisher-name>Elsevier Science</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">2713779</article-id>
      <article-id pub-id-type="pmid">19486956</article-id>
      <article-id pub-id-type="publisher-id">JVAC9290</article-id>
      <article-id pub-id-type="doi">10.1016/j.vaccine.2009.05.035</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Response to “Poor control vaccines in two randomised trials of malaria vaccine?”</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bejon</surname>
            <given-names>Philip</given-names>
          </name>
          <email>pbejon@well.ox.ac.uk</email>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="cor1" ref-type="corresp">⁎</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abdulla</surname>
            <given-names>Salim</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lusingu</surname>
            <given-names>John</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">c</xref>
          <xref rid="aff4" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Olotu</surname>
            <given-names>Ally</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Leach</surname>
            <given-names>Amanda</given-names>
          </name>
          <xref rid="aff5" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lievens</surname>
            <given-names>Marc</given-names>
          </name>
          <xref rid="aff5" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tanner</surname>
            <given-names>Marcel</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">b</xref>
          <xref rid="aff6" ref-type="aff">f</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>von Seidlein</surname>
            <given-names>Lorenz</given-names>
          </name>
          <xref rid="aff7" ref-type="aff">g</xref>
          <xref rid="aff3" ref-type="aff">c</xref>
          <xref rid="aff4" ref-type="aff">d</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <addr-line><sup>a</sup>Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute, Kilifi, Kenya</addr-line>
      </aff>
      <aff id="aff2">
        <addr-line><sup>b</sup>Bagamoyo Research and Training Centre of Ifakara Health Institute, Bagamoyo, Tanzania</addr-line>
      </aff>
      <aff id="aff3">
        <addr-line><sup>c</sup>The National Institute for Medical Research, Tanga Centre, Tanzania</addr-line>
      </aff>
      <aff id="aff4">
        <addr-line><sup>d</sup>The Joint Malaria Programme, Korogwe, Tanzania</addr-line>
      </aff>
      <aff id="aff5">
        <addr-line><sup>e</sup>GlaxoSmithKline Biologicals, Rixensart, Belgium</addr-line>
      </aff>
      <aff id="aff6">
        <addr-line><sup>f</sup>The Swiss Tropical Institute, Basel, Switzerland</addr-line>
      </aff>
      <aff id="aff7">
        <addr-line><sup>g</sup>The International Vaccine Institute, Seoul, Republic of Korea</addr-line>
      </aff>
      <author-notes>
        <corresp id="cor1"><label>⁎</label>Corresponding author at: Oxford University, CCVTM, Churchill Hospital, Old Road, Oxford OX3 7LJ, United Kingdom. Tel.: +44 770 4344 007.</corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>30</day>
        <month>7</month>
        <year>2009</year>
      </pub-date>
      <volume>27</volume>
      <issue>35</issue>
      <fpage>4745</fpage>
      <lpage>4746</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>4</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2009 Elsevier Ltd.</copyright-statement>
        <copyright-year>2009</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license>
          <p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</p>
        </license>
      </permissions>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Malaria</kwd>
        <kwd>Falciparum</kwd>
        <kwd>Vaccine</kwd>
        <kwd>RTS,S</kwd>
        <kwd>Safety</kwd>
        <kwd>Rabies</kwd>
        <kwd>Hepatitis B</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>We note the comments of Dr. Aaby <xref rid="bib1" ref-type="bibr">[1]</xref> on 4 March 2009 regarding the use of control vaccinations in our recent studies of RTS,S/AS01E in 5–17-month-old children <xref rid="bib2" ref-type="bibr">[2]</xref> and RTS,S/AS02D combined with the EPI schedule in young infants <xref rid="bib3" ref-type="bibr">[3]</xref>.</p>
    <p>Dr. Aaby and co-workers are concerned that the apparent reduction in severe adverse events (SAEs) in the RTS,S groups may represent an adverse consequence of the control vaccines (rabies and hepatitis B vaccines). To evaluate this hypothesis Dr. Aaaby and co-workers request: “we hope the authors will report the malaria and non-malaria serious adverse events and vaccine efficacy in the two trials separately for each sex” <xref rid="bib1" ref-type="bibr">[1]</xref>.</p>
    <p>Many parents, the FDA, local regulatory authorities and IRBs, want children to benefit from a vaccine rather than a placebo where an appropriate choice for a control exists. Young children are at risk of rabies in East Africa, and the disease is fatal if acquired. Pre-exposure prophylaxis is not widespread in Kenya and Tanzania, but is of proven benefit <xref rid="bib4" ref-type="bibr">[4]</xref>. The licensed human diploid-cell rabies vaccine (rabies vaccine BP, Sanofi-Pasteur) was therefore an appropriate control for RTS,S/AS01E vaccination of 5–17-month-old children.</p>
    <p>In EPI (extended programme of immunisation) schedules children are routinely vaccinated against hepatitis B, and it would not have been acceptable to withhold this vaccination in the control group <xref rid="bib5" ref-type="bibr">[5]</xref>. RTS,S/AS02D includes the hepatitis B surface antigen. It raises an antibody response to this antigen in infants <xref rid="bib6" ref-type="bibr">[6]</xref>, and so replaces the hepatitis B vaccine that would otherwise have been part of the EPI schedule. The design of both trials was approved by IRB and regulatory authority review.</p>
    <p>Dr. Aaby and co-workers have described non-specific deleterious effects of inactivated vaccines in Sub-Saharan Africa <xref rid="bib7" ref-type="bibr">[7]</xref>. In Dr. Aaby's work non-specific vaccine effects were particularly noted in girls rather than boys <xref rid="bib8" ref-type="bibr">[8]</xref>. He therefore proposes we re-analyse our safety data separately by gender. In 5–17-month-old children the SAE rates by vaccination allocation appeared consistent by girls and boys (<xref rid="tbl1" ref-type="table">Table 1</xref>). In the EPI schedule trial, the difference in SAE rates by vaccination was more pronounced for boys than girls (<xref rid="tbl2" ref-type="table">Table 2</xref>). The difference in pneumonia SAEs was also more pronounced for boys.</p>
    <p>Efficacy against clinical malaria was 53% (95%CI 28–69) in all 5–17-month-old children <xref rid="bib2" ref-type="bibr">[2]</xref>, compared with 63% (95% CI 29–81) in boys and 41% (95% CI −3 to 67) in girls. Efficacy against first infection was 65% (95%CI, 21–85) in the EPI study <xref rid="bib3" ref-type="bibr">[3]</xref>, compared with 52% (95%CI −40 to 84) in boys and 75% (95%CI 6–93) in girls.</p>
    <p>Our phase II studies were not designed to examine inpatient morbidity in detail. Phase III studies to clarify these findings are underway. There seems little evidence of a non-specific effect by Dr. Aaby's proposed analysis, and control vaccinations will be used in accordance with regulatory authority and IRB advice.</p>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <label>[1]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aaby</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Ravn</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Benn</surname>
              <given-names>C.S.</given-names>
            </name>
          </person-group>
          <article-title>Poor control vaccines in two randomised trials of malaria vaccine?</article-title>
          <source>Vaccine</source>
          <year>2009</year>
        </citation>
      </ref>
      <ref id="bib2">
        <label>[2]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bejon</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lusingu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Olotu</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Leach</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lievens</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Vekemans</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of RTS, S/AS01E vaccine against malaria in children 5–17 months of age</article-title>
          <source>N Engl J Med</source>
          <year>2008</year>
          <volume>359</volume>
          <issue>24</issue>
          <fpage>2521</fpage>
          <lpage>2532</lpage>
          <pub-id pub-id-type="pmid">19064627</pub-id>
        </citation>
      </ref>
      <ref id="bib3">
        <label>[3]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abdulla</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Oberholzer</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Juma</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Kubhoja</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Machera</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Membi</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Safety and immunogenicity of RTS, S/AS02D malaria vaccine in infants</article-title>
          <source>N Engl J Med</source>
          <year>2008</year>
          <volume>359</volume>
          <issue>24</issue>
          <fpage>2533</fpage>
          <lpage>2544</lpage>
          <pub-id pub-id-type="pmid">19064623</pub-id>
        </citation>
      </ref>
      <ref id="bib4">
        <label>[4]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Manning</surname>
              <given-names>S.E.</given-names>
            </name>
            <name>
              <surname>Rupprecht</surname>
              <given-names>C.E.</given-names>
            </name>
            <name>
              <surname>Fishbein</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hanlon</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Lumlertdacha</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Guerra</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Human rabies prevention—United States, 2008 recommendations of the Advisory Committee on Immunization Practices</article-title>
          <source>MMWR Recomm Rep</source>
          <year>2008</year>
          <volume>57</volume>
          <issue>RR-3</issue>
          <fpage>1</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="pmid">18496505</pub-id>
        </citation>
      </ref>
      <ref id="bib5">
        <label>[5]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Global progress toward universal childhood hepatitis B vaccination</surname>
            </name>
          </person-group>
          <article-title>52(36)</article-title>
          <source>MMWR Morb Mortal Wkly Rep</source>
          <year>2003</year>
          <fpage>868</fpage>
          <lpage>870</lpage>
          <pub-id pub-id-type="pmid">12970620</pub-id>
        </citation>
      </ref>
      <ref id="bib6">
        <label>[6]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aponte</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Aide</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Renom</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Mandomando</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Bassat</surname>
              <given-names>Q.</given-names>
            </name>
            <name>
              <surname>Sacarlal</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial</article-title>
          <source>Lancet</source>
          <year>2007</year>
          <volume>370</volume>
          <issue>9598</issue>
          <fpage>1543</fpage>
          <lpage>1551</lpage>
          <pub-id pub-id-type="pmid">17949807</pub-id>
        </citation>
      </ref>
      <ref id="bib7">
        <label>[7]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aaby</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Benn</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Lisse</surname>
              <given-names>I.M.</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>DTP vaccination and child survival in observational studies with incomplete vaccination data</article-title>
          <source>Trop Med Int Health</source>
          <year>2007</year>
          <volume>12</volume>
          <issue>1</issue>
          <fpage>15</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="pmid">17207144</pub-id>
        </citation>
      </ref>
      <ref id="bib8">
        <label>[8]</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aaby</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Vessari</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Maleta</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Benn</surname>
              <given-names>C.S.</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Sex differential effects of routine immunizations and childhood survival in rural Malawi</article-title>
          <source>Pediatr Infect Dis J</source>
          <year>2006</year>
          <volume>25</volume>
          <issue>8</issue>
          <fpage>721</fpage>
          <lpage>727</lpage>
          <pub-id pub-id-type="pmid">16874172</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
  <floats-wrap>
    <table-wrap position="float" id="tbl1">
      <label>Table 1</label>
      <caption>
        <p>Study of 5–17-month-old children <xref rid="bib2" ref-type="bibr">[2]</xref>.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th colspan="2" align="left">RTS,S/AS01E</th>
            <th colspan="2" align="left">Rabies</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="5" align="left">
              <bold>All subjects</bold>
            </td>
          </tr>
          <tr>
            <td align="left">Severe adverse events, per-subject analysis</td>
            <td align="left"><italic>N</italic> = 447</td>
            <td align="left">Percent (95% CI)</td>
            <td align="left"><italic>N</italic> = 447</td>
            <td align="left">Percent (95% CI)</td>
          </tr>
          <tr>
            <td align="left">Any SAE</td>
            <td align="left">47</td>
            <td align="left">11 (8–14)</td>
            <td align="left">82</td>
            <td align="left">18 (15–22)</td>
          </tr>
          <tr>
            <td align="left">SAE in absence of <italic>P. falciparum</italic> infection</td>
            <td align="left">41</td>
            <td align="left">9 (8–14)</td>
            <td align="left">61</td>
            <td align="left">14 (11–17)</td>
          </tr>
          <tr>
            <td align="left">Pneumonia</td>
            <td align="left">18</td>
            <td align="left">4 (2–6)</td>
            <td align="left">26</td>
            <td align="left">6 (4–8)</td>
          </tr>
          <tr>
            <td align="left">Gastroenteritis</td>
            <td align="left">10</td>
            <td align="left">2 (1–4)</td>
            <td align="left">21</td>
            <td align="left">5 (3–7)</td>
          </tr>
          <tr>
            <td align="left"><italic>P. falciparum</italic> infection</td>
            <td align="left">7</td>
            <td align="left">2 (1–3)</td>
            <td align="left">21</td>
            <td align="left">5 (3–7)</td>
          </tr>
          <tr>
            <td align="left">SAE related to vaccination</td>
            <td align="left">1</td>
            <td align="left">&lt;1 (0–1)</td>
            <td align="left">0</td>
            <td align="left">0 (0–1)</td>
          </tr>
          <tr>
            <td align="left">Death</td>
            <td align="left">1</td>
            <td align="left">&lt;1 (0–1)</td>
            <td align="left">1</td>
            <td align="left">&lt;1 (0–1)</td>
          </tr>
          <tr>
            <td colspan="5" align="left">  </td>
          </tr>
          <tr>
            <td colspan="5" align="left">
              <bold>Boys</bold>
            </td>
          </tr>
          <tr>
            <td align="left">Severe adverse events, per-subject analysis</td>
            <td align="left"><italic>N</italic> = 217</td>
            <td/>
            <td align="left"><italic>N</italic> = 225</td>
            <td/>
          </tr>
          <tr>
            <td align="left">Any SAE</td>
            <td align="left">22</td>
            <td align="left">10 (7–15)</td>
            <td align="left">42</td>
            <td align="left">19 (14–24)</td>
          </tr>
          <tr>
            <td align="left">SAE in absence of <italic>P. falciparum</italic> infection</td>
            <td align="left">22</td>
            <td align="left">10 (7–15)</td>
            <td align="left">30</td>
            <td align="left">13 (9–18)</td>
          </tr>
          <tr>
            <td align="left">Pneumonia</td>
            <td align="left">10</td>
            <td align="left">5 (2–8)</td>
            <td align="left">12</td>
            <td align="left">5 (3–9)</td>
          </tr>
          <tr>
            <td align="left">Gastroenteritis</td>
            <td align="left">5</td>
            <td align="left">2 (1–5)</td>
            <td align="left">9</td>
            <td align="left">4 (2–8)</td>
          </tr>
          <tr>
            <td align="left"><italic>P. falciparum</italic> infection</td>
            <td align="left">1</td>
            <td align="left">&lt;1 (0–1)</td>
            <td align="left">10</td>
            <td align="left">4 (2–8)</td>
          </tr>
          <tr>
            <td align="left">SAE related to vaccination</td>
            <td align="left">0</td>
            <td align="left">0 (0–1)</td>
            <td align="left">0</td>
            <td align="left">0 (0–1)</td>
          </tr>
          <tr>
            <td align="left">Death</td>
            <td align="left">1</td>
            <td align="left">&lt;1 (0–1)</td>
            <td align="left">1</td>
            <td align="left">&lt;1 (0–1)</td>
          </tr>
          <tr>
            <td colspan="5" align="left">  </td>
          </tr>
          <tr>
            <td colspan="5" align="left">
              <bold>Girls</bold>
            </td>
          </tr>
          <tr>
            <td align="left">Severe adverse events, per-subject analysis</td>
            <td align="left"><italic>N</italic> = 230</td>
            <td/>
            <td align="left"><italic>N</italic> = 222</td>
            <td/>
          </tr>
          <tr>
            <td align="left">Any SAE</td>
            <td align="left">25</td>
            <td align="left">11 (7–16)</td>
            <td align="left">40</td>
            <td align="left">18 (13–24)</td>
          </tr>
          <tr>
            <td align="left">SAE in absence of <italic>P. falciparum</italic> infection</td>
            <td align="left">19</td>
            <td align="left">10 (6–15)</td>
            <td align="left">31</td>
            <td align="left">14 (10–19)</td>
          </tr>
          <tr>
            <td align="left">Pneumonia</td>
            <td align="left">8</td>
            <td align="left">4 (2–7)</td>
            <td align="left">14</td>
            <td align="left">6 (4–10)</td>
          </tr>
          <tr>
            <td align="left">Gastroenteritis</td>
            <td align="left">5</td>
            <td align="left">2 (1–5)</td>
            <td align="left">12</td>
            <td align="left">5 (3–9)</td>
          </tr>
          <tr>
            <td align="left"><italic>P. falciparum</italic> infection</td>
            <td align="left">6</td>
            <td align="left">3 (1–6)</td>
            <td align="left">11</td>
            <td align="left">5 (3–9)</td>
          </tr>
          <tr>
            <td align="left">Related to vaccination</td>
            <td align="left">1</td>
            <td align="left">&lt;1 (0–1)</td>
            <td align="left">0</td>
            <td align="left">0 (0–1)</td>
          </tr>
          <tr>
            <td align="left">Death</td>
            <td align="left">0</td>
            <td align="left">0 (0–1)</td>
            <td align="left">0</td>
            <td align="left">0 (0–1)</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
    <table-wrap position="float" id="tbl2">
      <label>Table 2</label>
      <caption>
        <p>Study of young infants <xref rid="bib3" ref-type="bibr">[3]</xref>.</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th colspan="2" align="left">RTS,S/AS02D</th>
            <th colspan="2" align="left">Hep B vaccine</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="5" align="left">
              <bold>All subjects</bold>
            </td>
          </tr>
          <tr>
            <td align="left">Severe adverse events, per-subject analysis</td>
            <td align="left"><italic>N</italic> = 170</td>
            <td align="left">Percent (95% CI)</td>
            <td align="left"><italic>N</italic> = 170</td>
            <td align="left">Percent (95% CI)</td>
          </tr>
          <tr>
            <td align="left">Any SAE</td>
            <td align="left">31</td>
            <td align="left">18 (13–25)</td>
            <td align="left">42</td>
            <td align="left">25 (18–32)</td>
          </tr>
          <tr>
            <td align="left"><italic>P. falciparum</italic> infection</td>
            <td align="left">2</td>
            <td align="left">1 (0–4)</td>
            <td align="left">7</td>
            <td align="left">4 (2–8)</td>
          </tr>
          <tr>
            <td align="left">SAE in absence of <italic>P. falciparum</italic> infection</td>
            <td align="left">29</td>
            <td align="left">17 (12–24)</td>
            <td align="left">40</td>
            <td align="left">24 (17–31)</td>
          </tr>
          <tr>
            <td align="left">Pneumonia</td>
            <td align="left">10</td>
            <td align="left">6 (3–11)</td>
            <td align="left">28</td>
            <td align="left">17 (11–23)</td>
          </tr>
          <tr>
            <td align="left">Gastroenteritis</td>
            <td align="left">8</td>
            <td align="left">5 (2–9)</td>
            <td align="left">5</td>
            <td align="left">3 (1–7)</td>
          </tr>
          <tr>
            <td align="left">Anemia</td>
            <td align="left">2</td>
            <td align="left">1 (0–4)</td>
            <td align="left">8</td>
            <td align="left">5 (2–9)</td>
          </tr>
          <tr>
            <td align="left">Death</td>
            <td align="left">0</td>
            <td align="left">0 (0–2)</td>
            <td align="left">1</td>
            <td align="left">&lt;1 (0–3)</td>
          </tr>
          <tr>
            <td colspan="5" align="left">  </td>
          </tr>
          <tr>
            <td colspan="5" align="left">
              <bold>Boys</bold>
            </td>
          </tr>
          <tr>
            <td align="left">Severe adverse events, per-subject analysis</td>
            <td align="left"><italic>N</italic> = 79</td>
            <td/>
            <td align="left"><italic>N</italic> = 85</td>
            <td/>
          </tr>
          <tr>
            <td align="left">Any SAE</td>
            <td align="left">16</td>
            <td align="left">20 (12–31)</td>
            <td align="left">26</td>
            <td align="left">31 (21–42)</td>
          </tr>
          <tr>
            <td align="left"><italic>P. falciparum</italic> infection</td>
            <td align="left">1</td>
            <td align="left">1 (0–7)</td>
            <td align="left">6</td>
            <td align="left">7 (3–15)</td>
          </tr>
          <tr>
            <td align="left">SAE in absence of <italic>P. falciparum</italic> infection</td>
            <td align="left">15</td>
            <td align="left">19 (11–29)</td>
            <td align="left">24</td>
            <td align="left">28 (19–39)</td>
          </tr>
          <tr>
            <td align="left">Pneumonia</td>
            <td align="left">5</td>
            <td align="left">6 (2–14)</td>
            <td align="left">19</td>
            <td align="left">22 (14–33)</td>
          </tr>
          <tr>
            <td align="left">Gastroenteritis</td>
            <td align="left">4</td>
            <td align="left">5 (1–13)</td>
            <td align="left">5</td>
            <td align="left">6 (2–13)</td>
          </tr>
          <tr>
            <td align="left">Anemia</td>
            <td align="left">1</td>
            <td align="left">1 (0–7)</td>
            <td align="left">6</td>
            <td align="left">7 (3–15)</td>
          </tr>
          <tr>
            <td align="left">Death</td>
            <td align="left">0</td>
            <td align="left">0 (0–5)</td>
            <td align="left">1</td>
            <td align="left">1 (0–6)</td>
          </tr>
          <tr>
            <td colspan="5" align="left">  </td>
          </tr>
          <tr>
            <td colspan="5" align="left">
              <bold>Girls</bold>
            </td>
          </tr>
          <tr>
            <td align="left">Severe adverse events, per-subject analysis</td>
            <td align="left"><italic>N</italic> = 91</td>
            <td/>
            <td align="left"><italic>N</italic> = 85</td>
            <td/>
          </tr>
          <tr>
            <td align="left">Any SAE</td>
            <td align="left">15</td>
            <td align="left">17 (10–26)</td>
            <td align="left">16</td>
            <td align="left">19 (11–29)</td>
          </tr>
          <tr>
            <td align="left"><italic>P. falciparum</italic> infection</td>
            <td align="left">1</td>
            <td align="left">1 (0–6)</td>
            <td align="left">1</td>
            <td align="left">1 (0–6)</td>
          </tr>
          <tr>
            <td align="left">SAE in absence of <italic>P. falciparum</italic> infection</td>
            <td align="left">14</td>
            <td align="left">15 (9–25)</td>
            <td align="left">16</td>
            <td align="left">19 (11–29)</td>
          </tr>
          <tr>
            <td align="left">Pneumonia</td>
            <td align="left">5</td>
            <td align="left">5 (2–12)</td>
            <td align="left">9</td>
            <td align="left">11 (5–19)</td>
          </tr>
          <tr>
            <td align="left">Gastroenteritis</td>
            <td align="left">4</td>
            <td align="left">4 (1–11)</td>
            <td align="left">0</td>
            <td align="left">0 (0–4)</td>
          </tr>
          <tr>
            <td align="left">Anemia</td>
            <td align="left">1</td>
            <td align="left">1 (0–6)</td>
            <td align="left">2</td>
            <td align="left">2 (0–8)</td>
          </tr>
          <tr>
            <td align="left">Death</td>
            <td align="left">0</td>
            <td align="left">0 (0–4)</td>
            <td align="left">0</td>
            <td align="left">0 (0–4)</td>
          </tr>
        </tbody>
      </table>
    </table-wrap>
  </floats-wrap>
</article>